Theralase Technologies (TSXV:TLT) has shown in pre-clinical data that its flagship Rutherrin, when activated by X-Ray, is ...

Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...

Please provide your email address to receive an email when new articles are posted on . Patients with advanced muscle-invasive bladder cancer had lower risk for local recurrence with adjuvant ...

From a biomarker-driven strategy to delay or avoid cystectomy, to practice-changing perioperative immunotherapy, developments in bladder cancer frequently have made news over the past 12 months. The ...

A personalized strategy of dose-escalated radiotherapy (RT) for bladder cancer had a low rate of severe late toxicity and survival comparable to historical results with cystectomy, a randomized trial ...

Whole pelvis radiation improves cancer-specific and overall survival in muscle-invasive bladder cancer compared to bladder-only radiation. Median cancer-specific survival was 84 months for whole ...

Radiation therapy could be an underused tool to reduce pelvic relapse risk for patients with locally advanced, muscle-invasive bladder cancer, according to results of a new phase III randomized trial.

Bladder cancer radiotherapy has evolved significantly over recent years, with adaptive treatment techniques offering a promising approach to overcome the inherent challenges associated with treating a ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

Bottom line: Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had ...

When you learn you have bladder cancer, it’s only natural to ask: "Can I survive this, for how long, and can I expect to be cured?" You may have searched online for survival rate information. These ...